Assembly Biosciences (NASDAQ:ASMB) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Thursday.
Other analysts have also issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. BidaskClub raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, August 18th. Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research report on Wednesday, November 15th. Finally, Jefferies Group started coverage on shares of Assembly Biosciences in a research report on Wednesday, November 8th. They set a “buy” rating and a $50.00 price target on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Assembly Biosciences presently has an average rating of “Buy” and an average price target of $40.67.
Shares of Assembly Biosciences (ASMB) opened at $44.28 on Thursday. Assembly Biosciences has a 12-month low of $11.07 and a 12-month high of $52.37.
In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $49.37, for a total value of $49,370.00. Following the completion of the sale, the director now owns 20,465 shares in the company, valued at approximately $1,010,357.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 3,000 shares of company stock valued at $112,620 in the last quarter. 19.60% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors acquired a new stake in Assembly Biosciences in the 2nd quarter valued at approximately $161,000. Parametric Portfolio Associates LLC increased its holdings in Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 1,203 shares during the last quarter. Legal & General Group Plc acquired a new stake in Assembly Biosciences in the 2nd quarter valued at approximately $212,000. Wells Fargo & Company MN acquired a new stake in Assembly Biosciences in the 2nd quarter valued at approximately $213,000. Finally, Trexquant Investment LP acquired a new stake in Assembly Biosciences in the 2nd quarter valued at approximately $217,000. Hedge funds and other institutional investors own 62.09% of the company’s stock.
WARNING: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/09/assembly-biosciences-asmb-stock-rating-lowered-by-valuengine.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.